Mipomersen Phase 3 Study In Patients With Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
Links shared publicly online about this topic.
- 1,387total visits
Mipomersen Phase 3 Study In Patients With Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
mnt.to —
View full resource at mnt.to
Tags: Pharma, Phase 3 Clinical Trial, Genzyme
Most Recently Shared on February 12, 2010 at 11:38 am By:
MedicalNewsToday: Mipomersen Phase 3 Study In Patients With Heterozygous Familial: http://bit.ly/bka8e4 Full http://bit.ly/dn0m0P
Mipomersen Phase 3 Study In Patients With Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
medicalnewstoday.com — “Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its” View full resource at medicalnewstoday.com
Most Recently Shared on February 12, 2010 at 1:16 pm By:
MNT Cholesterol News Health News
Mipomersen Phase 3 Study In Patients With Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint http://mnt.to/3xxC #cholesterol
Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint - FierceBiotech
fiercebiotech.com — “Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint 28 Percent LDL-C Reduction in High-Risk Patient Population CAMBRIDGE, Mass. & CARLSBAD, Read more...” View full resource at fiercebiotech.com
Most Recently Shared on February 10, 2010 at 1:02 pm By:
RT @adamfeuerstein: Isis side effects (liver enzyme elevations) will tell the tale of mipomersen. Few details in PR. http://is.gd/8516i
Advertisement
